Molecular Partners and Orano Med present promising preclinical data for ovarian cancer treatment

From GlobeNewswire: 2025-06-22 16:00:00

MP0726, a Radio-DARPin candidate targeting mesothelin for ovarian cancer, is nominated for development by Molecular Partners and Orano Med. In vivo results show promising tumor accumulation and selective binding to membrane-bound MSLN with a positive tumor to kidney ratio of up to 4.5. The collaboration aims to address unmet medical needs, with MP0726 being the second Radio-DARPin program moving into pre-clinical development. Molecular Partners’ DARPin platform combines with 212Pb for targeted alpha radio-therapeutics, with future plans to target up to ten different proteins. Orano Med, a subsidiary of the Orano Group, is leading the development of lead-212 based therapies against cancer.



Read more at GlobeNewswire: Molecular Partners and Orano Med present preclinical data